Search Results

By Matthew Stenger  / Wednesday, April 15, 2015 10:51 AM

No Survival Benefit of Vorinostat in Progressive Advanced Malignant Pleural Mesothelioma

In the phase III VANTAGE-014 study reported in The Lancet Oncology, Krug et al found that treatment with the histone deacetylase inhibitor vorinostat (Zolinza) did not improve overall survival vs placebo in patients with malignant pleural mesothelioma who had progressed on previous chemotherapy....